Roivant Sciences Net Income decreased by 88.9% to -$313.70M in Q4 2025 compared to the prior quarter. Year-over-year, this metric declined by 365.7%, from $118.08M to -$313.70M. Over 3 years (FY 2021 to FY 2024), Net Income shows an upward trend with a -29.9% CAGR. This decline may warrant attention — for this metric, higher values are generally preferred.
An increase indicates higher profitability and operational success, while a decrease may signal rising costs or declining sales.
Net income represents the total profit of the company after all operating expenses, taxes, and interest have been deduct...
Standard across all public companies, though margins vary significantly by industry sector.
net_income_cf| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | -$101.08M | -$225.64M | -$306.09M | -$291.31M | -$353.78M | -$315.92M | -$384.90M | -$60.86M | -$327.85M | -$331.12M | $5.07B | $0.00 | $95.30M | -$279.92M | $118.08M | -$252.38M | -$223.36M | -$166.04M | -$313.70M |
| QoQ Change | — | -123.2% | -35.7% | +4.8% | -21.4% | +10.7% | -21.8% | +84.2% | -438.7% | -1.0% | >999% | -100.0% | — | -393.7% | +142.2% | -313.7% | +11.5% | +25.7% | -88.9% |
| YoY Change | — | — | — | — | -250.0% | -40.0% | -25.7% | +79.1% | +7.3% | -4.8% | >999% | +100.0% | +129.1% | +15.5% | -97.7% | — | -334.4% | +40.7% | -365.7% |
| Segment | Q3 '25 | Q4 '25 |
|---|---|---|
| Reportable Segment | -$166.04M | -$313.70M |
| Total | -$166.04M | -$313.70M |